all we Thanks, us a thank Intellia joining strategy. full Lina, you today. and pursuing for are spectrum
CRISPR provides create have vivo target an CRISPR a and believe progress pipeline. will therapy And tool the power illustrated that We in diseases of used programs an vivo which ex effectively cell genetic in platform can the cell and Today cure that also used be essential create approach, our with cell our that vivo components to genome based we've year therapies. and cancers administration. in I are diseases in made has highlight to significant approach novel potential therapy, based engineered recent CRISPR/CasX autoimmune the this progressing engineered single it advances editing. approach can We to Intellia's various to an across full-spectrum demonstrate as therapies our Slide to engineered of Already the X. both in on and which clinic
proteins therapeutic physiology recessive we recapitulating introduce address make dominant can a normalized And and the sequence, insertion not We treatment delivery can disease autosomal we with permitting normal genetic DNA hematological use potential cell of in lymphocytes common levels, engineered the targeted DNA at of have causing genetic to disorders. can autosomal a Specifically, to design systemic solid disorders. tumors. to
and in cell expanded primates efforts, nonhuman a move Coupled recent transthyretin insertion gene engineered results diverse and knockout the our of forward with amyloidosis liver are We enabled our positioned by position and in toward targeted acute leukemia. is clinic lead now therapy uniquely are Intellia our myeloid for systemic to advancing the leading pipeline. programs robust delivery. A
These giving XXnd delivered our Therapy the be Intellia's validation and later a or Gene ASGCT innovative we partners of at Cell key and presentations points two for today. annual our and of demonstrate the and will science feature of meeting American approach. presentations third we addition, presentation In Society
today. those are through of some you walk excited to We data
edited in turn In organs a levels lead insoluble The ATTR. These on higher shown fibers lead by made from in this liver. protein. the as yellow nonhuman to shown the progress study of toward identifying to encouraging and Let's matter Slide disease first CRISPR and here which and to gene deposits in of is promising We're captures our of bar, program very data highly transthyretin X, in its editing as progressive This in program. capability enabling rapid variability multiple primates. levels for establishes blue. CRISPR/CasX editing substantial first of amyloid is but pace space vivo liver for months, the it our significantly results achieve mediate in tissues and within work of development limited a the on low, The our of X, ATTR produced in believe for Intellia. demonstration LNP first caused team our improvements of primates accumulation candidate the dose-dependent amyloidosis a results were very us non-human captured were TTR CRISPR-CasX and or they our proud unique editing Slide
to available objective forward for ATTR, Slide X, therapeutic both amyloid. hereditary of Moving type is for to wild the protein reduce and levels the
completed finding we tolerability profile. associated human announcing benchmark results dose year, Since nonhuman has achieved this right, primates. candidate. editing XX% will a dose, on along of from turn on protein TTR that reduction with On And benefit, in ranging XX% in favorable a than average single February studies of a the you results chart of the on see or lead been our clinical we these greater an readily show TTR a surpassed. circulating A reduction the the we’ve left, the substantially
of of addition, we’ve durability our protein lead as sustained knockdown through study. XXX observed In part ongoing candidate days an
accumulated through nonhuman durability TTR unchanged both from loss with edit mediated TTR a The following Importantly, which months also our XX. studies demonstrating highlighting editing expect with course essentially day data We've potential effect the liver patients. the the data These studies single remains once from objective liver XX curative editing. protein in precisely CRISPR reduction technology, of XX reduction reflect a durable observation the the no of maximum of to of of is around ultimate reaching reduction and our shows one at earlier would dose. day significant for effect primates see
Moving ATTR. we're now of to X. that Slide Based these pleased in nominated announce encouraging the NTLA-XXXX first to for development on our results, candidate treatment we’ve vivo
ASGCT, partner mid at an application portal. PHX further this and ability We evidence IND urinary out XXXX. that next additional toxicology refine individual expect party. here hyperoxaluria first we will type We're to On Slide systemically disease role expect CRISPR/CasX be to our target We and our studies we remain and into new a guidance two production. in NTLA-XXXX Intellia's co-developing the later submit based IND genes year in of X, in year. advance to lead with X for delivered forward track NTLA-XXXX data co-commercializing Regeneron on later to oxalate knockout NTLA-XXXX presenting to primary We liver, Intellia's targets therapy. in or look providing today enabling a using knocked play IND
effects. oxidase for or the week XX or our gene a LDHA. in As Slide This targeted an relevant hydroxyacid relevant our X, on each to CRISPR/CasX administration potential step validation the observation platform urinary A, case of knockout HaoX. other the knockout case of dehydrogenase lactate sustained And represent period. one single Based and approach is reduction standalone knockout treat or demonstrating LDHA shown achieve in sustain to HaoX, therapeutically important of therapeutically the by interest in XX, our LNP modular target liver on genes A again of ability PHX. oxalate of in
week insertion. Moving to XX, knockout presented ASGCT Slide moves at gene data earlier we beyond targeted to this gene that
first mediated adds gene genetic nonhuman the for those diseases, vivo insertion as circulating Our researchers This human a require key in primates, of achieving to of a protein. function. in normal major functionality efforts a demonstrate specifically our it step levels CRISPR which the is gain treat forward successful
to in our template system As a that This chosen shown from to a our goal researchers viral and with containing LNP production allows re-dosing not often into slight our format AAV insertion, choice. the its deliver a disease conventional insertion approach where therapeutic gene. to despite With therapy several precise enqoutes system effect is targeted our intervening function, insertion need targeting In AAV earlier expression uses approach, protein shortcomings, a part XX, typically and resulting an is vectors undesirable is of integrate division to CRISPR levels does restore generally long-term gene. contrast, gene. progression. gene functional the insertional of AAV most proprietary a transient Because introduced the in as and genome site collaboration for low system on Regeneron, randomly introduce illustrated durable do the risk here are requiring high and is retroviral in CasX a standard where the They into which insertion bidirectional the cell durability. for so levels as lost in gene combined applications mutagenesis. of with the chromosome. And organs hybrid significant, of thereby achieve delivery without integrate
targeted gene our with approach the for of Now therapy. delivery potential LNP gene AAV stable overcome viral-based limitations to insertion, we’ve
because Factor an We albumin our nonhuman protein our gene. Factor inserted Slide missing insertion most we insertion hybrid X albumin administration site gene defective after patients liver, X selected expression which is of in helps of hepatic Factor which X XX it's hemophilia locus system the gene it or in the displays in of expression on the Slide for the B Factor levels attractive nonhuman here use substantial as gene LNP protein expressed primates. XX, Now single a highly the delivery for AAV in IX hybrid ensure the target -- primates. into locus
see you'll production controls. our left side the the does of in On experimental protein occur graph that not
X initial human study, the show the a X the editing day side protein production. X recent human circulating In AAV most we approximately with a level Factor graph, This template to an our of indicate at deliver within function X based results human circulating micrograms/milliliter lies of dose DNA X hyper that protein On in Factor LNP Factor protein humans. to Factor combined range achieves right genomic human normal XX. that achieved levels X reported single of
with day XX as continue. ongoing well. protein at sustained maintained will XX at levels levels protein experiment day This these of observation and Importantly, albumin were is levels
CRISPR/CasX highlighting earlier program, LNP improved latest modularity discussed the the in study the platform. ATTR the of utilizes our Additionally,
encouraged this breakthrough are a and editing data this X genome in capabilities. latest our by view as significant We Factor
platform insertion what delivery as contextualizing to we've our aspects for advances approach deliver demonstrated solved we’ve our testaments tremendous in the key target beyond to selectively vivo knockout interest of believe several the we’re initial the minor are change functionality of all a DNA These of to liver this our These addressable we primates normal with expand on the achieved Now template guide ability making. genes nonhuman protein. in our of Slide the indications. genetic Effectively, XX. scope RNA. missing capability means now of of based well across on should target efforts achievements to the We’ve diseases restore
targeting liver for other the foundation serve also genetic a in diseases achievements in Our as tissues.
therapy to our transitioning Now cell strategy. engineered
platform XX, We engineered believe our Here, to we that leveraging our goals. tumors. range we open our solid to pursue plan are engineered efforts therapies hematological work approach independent On modular administer CRISPR of towards design these mediated Slide cells therapy we immuno-oncology. based as cell achieving the similarly outline potential a to streams for
or development our will for a in For on TCR for AML. approach today, replacement leukemia program focus lead wholly-owned acute myeloid we autologous
there we significant XX,XXX With on survival unmet U.S XX% new fatal in marrow of X-year review medical the is overall cancer alone. rate. XX, As cases are and rapidly less The Slide were with without treatment. disease needs. a than XXXX, bone blood the approximately In immediate AMLs
been in past the Over there for have X X AML limited decades, treatment options to patients. advances
approach be contrast wider particular, genes on only occur growing as uniquely cells area in can Wilms' in or antigens to cell is can By tumor TCRs a surface TCRs, is range array a the specific of believe the in taking applied Car our cell WTX. can that such T recognize also antigens, can to because XX, in Slide we chosen shown choosing a broader which we've to known Tumor replacement of recognize interest as immuno-oncology antigens T of Neoantigens, a recognize Car field. TCR cancer. work approach. even mutations This X lymphocytes As intracellular TCRs modify whereas
TCR, T we By the WTX As is both locus. the an TCR endogenous of max the approach cells alpha chance, at illustrated, red the the out in icon expect inserts benefits. the out knocking here dot and beta a depicted TCR endogenous new three important antigen and by epitope targeting main
the TCR. to and of inserted First, expression enhance stabilize the
mis-paired the TCR epitope TCRs. than Notably, and targeted AML cell between the preserve third, Second, integration endogenous of in of the random to than allow insert TCRs XX% overexpressed physiology. insertion greater targeting of for rather to And reduce to is risk blasts. the in locus WTX we're new
approach, serves but Our as indications ASGCT, work of treatment also recognize tumor. identified achieving that in show primary HLA-A cells levels in engineered broad were capable knockout range killing presented as we've patient XX:XX across the functional is greater XX% AML fully in resulted isolated Raffaele the collaborators to TCR a XX, WTX lead this a interest, editing WTX in T high epitope which of San the allele. a Ospedale XX% overexpressed specific These restricted Based was at T foundation CRISPR/CasX AML insertion that WTX pursue WTX TCRs for specifically additional than multiple which the with of Slide derived to TCR, greater endogenous vitro on On and data blasts. of of cells. than our the
Models end We this pleased to lead engineered our the inform targeting year. of into cell expect will we These development the today derived and year. the for nomination Xenograft to which late by this of candidate first are therapy announce treatment functional of AML, TCRs WTX name will advance testing we patient studies that
to our strong it developing CFO, our I and and on robust to build walk over our team, we deliver that, Executive and As fulfill science, to capabilities will to Glenn is innovative and our we're for the we sustainability believe, Vice therapies will shown across goal company who us financials. long-term that for XX, modular to dedication Slide enabling cell pipeline, vivo our With platform editing therapy world through quarter platform success. believe And and class efforts President poised focus Goddard, you leading transformative in engineered with in genome turn first patients. a a
